Research programme: tyrosine kinase inhibitors - Paradigm Pharmaceuticals

Drug Profile

Research programme: tyrosine kinase inhibitors - Paradigm Pharmaceuticals

Alternative Names: JANEX-1; Tyrosine kinase inhibitors research programme - Paradigm Pharmaceuticals

Latest Information Update: 27 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Paradigm Pharmaceuticals
  • Class Quinazolines
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Graft-versus-host disease; Thromboembolism

Most Recent Events

  • 15 Oct 2004 Preclinical trials in Graft-versus-host disease in USA (unspecified route)
  • 15 Oct 2004 Preclinical trials in Thromboembolism in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top